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Abstract
Background: Effusive constrictive pericarditis (ECP) is visceral constriction in conjunction with compressive
pericardial effusion. The prevalence of proven tuberculous ECP is unknown. Whilst ECP is distinguished from
effusive disease on hemodynamic grounds, it is unknown whether effusive-constrictive physiology has a distinct
cytokine profile. We conducted a prospective study of prevalence and cytokine profile of effusive-constrictive disease
in patients with tuberculous pericardial effusion.
Methods: From July 2006 through July 2009, the prevalence of ECP and serum and pericardial levels of
inflammatory cytokines were determined in adults with tuberculous pericardial effusion. The diagnosis of ECP was
made by combined pericardiocentesis and cardiac catheterization.
Results: Of 91 patients evaluated, 68 had tuberculous pericarditis. The 36/68 patients (52.9%; 95% confidence
interval [CI]: 41.2-65.4) with ECP were younger (29 versus 37 years, P=0.02), had a higher pre-pericardiocentesis
right atrial pressure (17.0 versus 10.0 mmHg, P<0.0001), serum concentration of interleukin-10 (IL-10) (38.5 versus
0.2 pg/ml, P<0.001) and transforming growth factor-beta (121.5 versus 29.1 pg/ml, P=0.02), pericardial concentration
of IL-10 (84.7 versus 20.4 pg/ml, P=0.006) and interferon-gamma (2,568.0 versus 906.6 pg/ml, P=0.03) than effusive
non-constrictive cases. In multivariable regression analysis, right atrial pressure > 15 mmHg (odds ratio [OR] = 48,
95%CI: 8.7-265; P<0.0001) and IL-10 > 200 pg/ml (OR=10, 95%CI: 1.1, 93; P=0.04) were independently associated
with ECP.
Conclusion: Effusive-constrictive disease occurs in half of cases of tuberculous pericardial effusion, and is
characterized by greater elevation in the pre-pericardiocentesis right atrial pressure and pericardial and serum IL-10
levels compared to patients with effusive non-constrictive tuberculous pericarditis.
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Introduction
Effusive-constrictive pericarditis (ECP) is a clinical syndrome
in which compressive pericardial fluid and a constricting
visceral pericardium occur simultaneously [1]. The definitive
diagnosis is established by demonstrating hemodynamics
consistent with constrictive pericarditis, following complete
drainage of pericardial effusion with normalization of intra-
pericardial pressure [2]. The importance of recognizing ECP is
that drainage of pericardial fluid alone when visceral
constriction is present is ineffective in relieving pericardial
compression; in the absence of visceral pericardiectomy,
clinical evidence of hemodynamic impairment may persist and
there may be progression to constrictive pericarditis over a
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short period of time [3]. Current prospective studies suggest
that ECP is an uncommon pericardial syndrome [4]. The
largest prospective study to date enrolled 15 patients after
screening 1184 patients with pericarditis over 15 years; the
prevalence of ECP amongst participants with pericardial
disease was 1.3% and 6.8% amongst those with tamponade
[1].
ECP is recognized as an important manifestation of
pericardial tuberculosis [5], a disease that is associated with
high morbidity and mortality [6,7]. There are, however, no
studies of tuberculous ECP that have used combined
pericardiocentesis and cardiac catheterization, the ‘gold
standard’ for the diagnosis of effusive-constrictive disease [8].
Furthermore, it is unknown whether ECP has a biomarker
profile that would shed light on the pathogenesis and
diagnostic approach of this unique pericardial syndrome that is
associated with inflammation and fibrosis. Cytokines such as
interleukin-1β (IL-1β), tumor necrosis factor- α (TNF-α) and
transforming growth factor β (TGF-β) have been implicated in
the development of fibrosis in the context of a chronic
inflammatory disease such as tuberculosis [9]. We postulated
that the unique combination of fluid exudation and visceral
constriction in effusive-constrictive disease may have a
distinctive cytokine profile. We present the results of the first
study of the prevalence and cytokine profile of proven effusive-
constrictive disease in patients with tuberculous pericardial
effusion.
Methods
This is a single center sub-study of the ongoing Investigation
of Management of Pericarditis in Africa (IMPI Africa) registry of
patients with suspected tuberculous pericarditis which was
approved by the University of Cape Town Human Research
Ethics Committee (HREC REF: 402/2005) [6]. This sub-study
was conducted at Groote Schuur Hospital in Cape Town, South
Africa. All participants gave written informed consent. The
study complies with the Declaration of Helsinki.
Definitions
Pericarditis was deemed to be tuberculous if one or more of
the following criteria were met: Mycobacterium tuberculosis (M.
tuberculosis) was identified on pericardial fluid microscopy,
culture or by polymerase chain reaction (i.e., definite
tuberculous pericarditis); and/or the pericardial fluid was a
lymphocytic exudate with an elevated interferon-gamma (IFN-
γ) (>50pg/ml) or adenosine deaminase (ADA) (>40U/L) level
(i.e., probable tuberculous pericarditis) [10].
ECP was established on the basis of the following
hemodynamic findings during combined pericardiocentesis and
cardiac catheterization: a) a pre-pericardiocentesis mean
pericardial pressure of > 8 mmHg, b) a pre-pericardiocentesis
transmural filling pressure gradient of ≤ 4 mmHg (i.e., the
difference between the right atrial pressure and the intra-
pericardial pressure), c) a post pericardiocentesis mean
pericardial pressure of 0±4 mmHg, and d) failure of the post-
pericardiocentesis mean right atrial pressure to fall below 11
mmHg or to fall by 50% of the pre-pericardiocentesis level.
Participants were considered to have hemodynamic
tamponade where there was a difference between the pre-
pericardiocentesis right atrial pressure and intra-pericardial
pressure of < 4 mmHg, i.e., the transmural pressure
approached zero [11]. Participants who did not meet these
criteria were considered to have effusive non-constrictive
tuberculous pericarditis.
Patients
From July 2006 through July 2009, 91 consecutive adults
with suspected tuberculous pericarditis underwent
simultaneous measurement of intra-pericardial and right heart
pressures, and estimation of transmural filling pressures with 6
French multipurpose catheters before and after sub-
xiphisternal pericardiocentesis using standard methods.
Participants were enrolled if they were ≥18 years of age, had
echocardiographic evidence of a pericardial effusion with at
least 1 cm of echo-free space anterior to the heart in
telediastole, and probable or definite tuberculous pericarditis as
indicated under definitions above [10]. They were excluded if
the hemodynamic data were not obtainable or incomplete (n 5),
and if the diagnosis of tuberculous pericarditis was not
confirmed (n 18).
The 68 patients with tuberculous pericarditis who met the
inclusion criteria underwent clinical evaluation by history,
physical examination, echocardiography and laboratory
analysis of cytokines in serum and pericardial fluid. Blood was
collected prior to pericardiocentesis in BD Vacutainer SSTTM
Advance vials (BD Diagnostics, UK) and pericardial fluid was
decanted into BD Vacutainer vials (BD Diagnostics, UK). Both
tubes were centrifuged at 3000 rpm for 10 minutes using a
Sigma 4K15 laboratory centrifuge with a swing-out rotor.
Serum and cell free pericardial fluid were collected and stored
in NUNC cryotube vials at -80°C until batch analysis was
performed. The following cytokines that are involved in the
regulation of inflammation and fibrosis were measured by
enzyme linked immunosorbent assay according to the
manufacturers’ instructions: eBioscience, USA: interleukin-1
beta (IL-1β), interleukin-6 (IL-6), and interleukin-17 (IL-17) [14];
Mabtech, Sweden: interleukin-10 (IL-10) ; KOMA Biotech,
Korea: interleukin-22 (IL-22) [12]; BD Pharmingen, USA:
interferon-gamma (IFN-γ) ; R&D Systems, USA: transforming
growth factor-beta (TGF- β) and tumor necrosis factor-alpha
(TNF-α). Pericardial biopsy was not performed in this study.
Statistical Methods
The sample size required to provide adequate power to
estimate the prevalence rate of ECP with a precision of 5%
was 54, based on the anticipated 15% prevalence rate of
tuberculous ECP from published literature [8]. The Shapiro-
Wilk test was used to assess the distribution of continuous
data. Baseline summary data are presented as medians with
inter-quartile ranges (IQR) for variables with skewed
distribution or means with standard deviation for variables with
normal distribution. Differences in continuous measures
between participants with or without ECP were tested using the
Student t-test or Mann-Whitney test. Categorical data were
Tuberculous Effusive-Constrictive Pericarditis
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compared using Pearson χ2 test or, where appropriate, the
Fisher exact test.
Logistic regression models were fitted to determine factors
associated with ECP. The following variables that were tested:
age, gender, history of tuberculosis, duration of symptoms,
New York Heart Association Functional Class, HIV status,
clinical signs of heart failure (i.e., jugular venous pressure,
pulse rate, pulsus paradoxus, peripheral edema),
electrocardiographic changes (i.e., heart rate, rhythm, and
chest lead voltage), chest radiograph abnormalities (i.e.,
presence of pleural effusion, active pulmonary tuberculosis or
evidence of previous tuberculosis), serum analysis (creatinine
phosphokinase (CK), CK-MB fraction, NT-pro brain natriuretic
peptide level, CD4 T cell count (in HIV positive individuals),
lactate dehydrogenase (LDH), and total protein), pericardial
fluid analysis (adenosine deaminase level, LDH, total protein,
microscopy for acid fast bacilli, M. tuberculosis culture, and
PCR), and invasive cardiac hemodynamic findings (pericardial
fluid volume, intra-pericardial pressure before and after
pericardiocentesis, right atrial pressure before and after
pericardiocentesis, and presence of hemodynamic changes of
cardiac tamponade). Variables found to be non-normally
distributed were modeled as binary categorical variables using
the first or the third quartile as a cut-off. Factors found
significantly associated with ECP in univariable models were
included in the final multivariable model. All tests were two-
sided, and a p-value <0.05 was considered significant. Data
analysis was performed with SPSS (version 17.0).
Results
Prevalence of Effusive-Constrictive Pericarditis
Ninety one participants with pericardial effusion were
referred to Groote Schuur Hospital for evaluation of suspected
tuberculous pericarditis. Sixty-eight of the 91 patients met the
diagnostic criteria for definite tuberculous pericarditis (n 41,
60%) and probable tuberculous pericarditis (n 27, 40%) and
had complete information on combined pericardiocentesis and
cardiac catheterization to enter the study. The prevalence of
ECP in patients with tuberculous pericardial effusion was
52.9% (95% CI: 41.2-65.4). Table 1 shows a summary of
baseline clinical and hemodynamic characteristics of patients
with ECP and the comparison group of patients with effusive
non-constrictive disease. The median age of the whole group
was 37 years (IQR 29.0-53.0), 61% were male and 74% were
co-infected with HIV-1. Compared to patients with effusive non-
constrictive disease, patients with ECP were younger (median
29 years, IQR 26.0-34.5 versus 37 years, IQR 29-53; P=0.02),
and had higher pre-pericardiocentesis right atrial pressure
(17.0 mmHg, IQR 15.0-20.0 versus 10.0 mmHg, IQR 8.3-13.0;
P<0.0001).
The mean (±SD) volume of pericardial fluid drained was
917±414 ml for the whole group. Tuberculosis was confirmed
by pericardial fluid culture in 60% (i.e., definite tuberculous
pericarditis) and established by ADA or IFN-γ level in the
remainder (i.e., probable tuberculous pericarditis). There was
no difference in gender, HIV seroprevalence, use of anti-
retroviral drugs and adjunctive corticosteroids, volume of
pericardial fluid drained, proportion with definite tuberculous
pericarditis, and frequency of pericardial tamponade between
the two groups (Table 1).
Cytokine Profile
Table 2 shows the pericardial and serum levels of cytokines
in the two groups. Patients with ECP had higher median levels
of IL-10 (38.5 versus 0.2 pg/ml, P<0.001) and TGF-β (121.5
versus 29.1 pg/ml, P=0.02) in the serum compared to those
with effusive non-constrictive pericarditis. In the pericardial
fluid, participants with ECP had higher median levels of IL-10
(84.7 versus 20.4 pg/ml, P=0.006) and IFN-γ (2568.0 versus
906.6 pg/ml, P=0.03) than those without. No differences were
noted between serum and pericardial fluid concentrations of
IL-1β, IL-6, IL-17, IL-22, and TNF-α. These findings were
independent of age, HIV status and whether or not the
pericardial fluid was culture positive for M. tuberculosis. IFN-γ
was not detected in the serum probably because ex-vivo levels
tend to be lower than the detection threshold of the assay of 50
pg/ml[13]. Likewise, TGF-β was not detectable in pericardial
fluid. Bioactive TGF-β, which was measured in this study, is
often very low or undetectable in tuberculous pericarditis which
is known to be a delayed type hypersensitivity response driven
predominantly by Th-1 cytokines (e.g., IL-10) and characterized
by the absence of TGF-β [14-16].
Table 1. Comparison of clinical and hemodynamic
characteristics of patients with tuberculous effusive-
constrictive pericarditis and effusive non-constrictive
pericarditis at the time of enrolment into the study.
 
Effusive-
constrictive
pericarditis
(N=36)
Effusive non-
constrictive
pericarditis
(N=32) P-value
Age: median (IQR) 29.0 (26.0-34.5) 37.0 (29.0-53.0) 0.02
Women (%) 39.0 35.0 0.71
HIV seropositive (%) 69.0 78.0 0.42
CD4+T-lymphocyte count (cells/
µl)in HIV infected individuals:
median (IQR)
172 (82-347) 154 (57-334) 0.62
HIV infected individuals receiving
anti-retroviral therapy at diagnosis
(%)
6 3 0.91
Definite tuberculous pericarditis (%) 61 59 0.48
Participants who received
adjunctive corticosteroids (%) 56 56 NA
Volume of pericardial fluid drained
(ml): median (IQR)
1010
(543-1477) 933 (519-1347) 0.48
Tamponade confirmed at right
heart study (%) 53.0 56.0 0.77
Pre-pericardiocentesis right atrial
pressure: median (IQR) 17.0 (15.0-20.0) 10.0 (8.3-13.0) <0.0001
IQR, inter-quartile rangeIQR: inter-quartile ranges
doi: 10.1371/journal.pone.0077532.t001
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Figure 1 is the visual representation of significant cytokine
differences when comparing effusive with effusive-constrictive
tuberculous pericarditis in the blood and pericardial fluid
compartments (see Table 2 for results of all cytokines). Each
colored disc represents the median value for the particular
cytokine; the areas are proportional to the concentration of the
cytokine. It is evident that the IFN-γ response in pericardial fluid
is significantly greater in effusive-constrictive disease
compared to that in effusive non-constrictive pericarditis. While
the IFNγ response is thought to be protective, this is countered
by an increased regulatory IL-10 response in pericardial fluid in
the effusive-constrictive form of the disease. The most striking
finding, however, is the extent to which IL-10 is elevated in
serum in effusive-constrictive tuberculous pericarditis, at a ratio
of 158 compared to effusive non-constrictive disease. Similarly,
the fibrotic and regulatory cytokine, TGF-β is significantly
elevated in the serum of effusive-constrictive tuberculous
pericarditis, leading to the hypothesis that the
immunopathology seen in ECP is largely driven by a
pathological cross-regulatory and fibrotic response which
abrogates the protective IFN-γ response, and leads to
structural changes in the visceral pericardium which are
manifested by constrictive physiology.
Table 2. Serum and pericardial cell-free fluid levels of
cytokines at baseline in patients with tuberculous effusive
constrictive and effusive non-constrictive pericardial
disease (all values in pg/ml).
CompartmentCytokine 
Effusive-
constrictive
pericarditis  
Effusive non-
constrictive
pericarditis P-value
  N Median (IQR) N Median (IQR)  
Serum IL-1β 33 7.1 (0.0-9.9) 29 7.8 (0.0-9.5) 0.90
 IL-6 31 7.9 (0.0-50.4) 28 29.1 (0.0-86.8) 0.65
 IL-10 31 38.5 (0.4-563.2) 29 0.2 (0.0-2.6) <0.001
 IL-17A 31 0.0 (0.0-13.0) 29 5.0 (0.0-14.9) 0.50
 IL-22 31 74.5 (0.0-597.4) 28 60.1 (0.0-846.0) 0.96
 IFN-γ 31 0.0 (0.0-0.0) 29 0.0 (0.0-37.6) NA
 TGF-β 31 121.5 (26.5-279.6) 29 29.1 (0.0-136.1) 0.02
 TNF-α 33 14.7 (0.0-109.8) 28 13.0 (0.0-50.3) 0.33
Pericardium IL-1β 33 8.7 (0.8-25.5) 28 9.8 (0.4-11.7) 0.79
 IL-6 31 1608.2(1218.4-4248.1) 28
1885.4
(1310.5-4993.4) 0.27
 IL-10 31 84.7 (0.9-392.7) 29 20.4 (0.0-62.2) 0.006
 IL-17A 31 0.0 (0.0-12.2) 29 3.6 (0.0-12.2) 0.49
 IL-22 31 349.5(128.3-901.2) 28
210.8
(21.0-1165.1) 0.41
 IFN-γ 31 2568.0(1318.0-6260.6) 29 906.6 (3.3-3447.4) 0.03
 TGF-β 31 0.0 (0.0-0.0) 30 0.0 (0.0-0.0) 0.97
 TNF-α 31 36.9 (8.6-113.0) 28 14.5 (7.7-50.0) 0.19
IQR, inter-quartile range IQR: inter-quartile ranges
doi: 10.1371/journal.pone.0077532.t002
Factors associated with effusive constrictive
pericarditis
In a multivariate regression model of factors associated with
ECP, only opening right atrial pressure > 15 mmHg (OR=48,
95%CI 8.7-265; P<0.0001) and IL-10 > 200 pg/ml (OR=10,
95%CI 1.1-93; P=0.04) were independently associated with the
syndrome (Table 3).
Discussion
We have described the first prospective study of the
prevalence and cytokine profile of hemodynamically proven
effusive-constrictive disease in tuberculous pericardial effusion.
We show that, contrary to non-tuberculous forms of pericardial
disease where effusive-constrictive disease is uncommon, ECP
occurs in half of cases of tuberculous pericardial effusion. In
addition, we demonstrate that tuberculous ECP has a unique
clinical, hemodynamic, and cytokine profile that is
characterized by a younger age of onset (about a decade
earlier than effusive non-constrictive disease), a high pre-
pericardiocentesis right atrial pressure on cardiac
catheterization, elevated serum and pericardial levels of IL-10,
serum TGF-β and pericardial IFN-γ compared to effusive non-
constrictive disease. Finally, we demonstrate for the first time
that pre-pericardiocentesis right atrial pressure and IL-10 level
were independently associated with effusive-constrictive
disease in patients with tuberculous pericardial effusion.
Previous studies of ECP have suggested that it is an
uncommon pericardial syndrome with a prevalence ranging
from 2.4% to 14.8%, possibly because they were conducted in
countries with a low prevalence of tuberculosis [8]. The current
state of knowledge on the frequency of tuberculous ECP is
based on studies that used clinical methods of diagnosis which
are less accurate than invasive hemodynamic tests. The first
prospective case series on the frequency of tuberculous ECP
suggested a low prevalence of 2.6% based on non-invasive
diagnostic criteria [17]. Subsequently, The IMPI Africa Registry
reported that tuberculous ECP accounted for 15% of cases of
suspected tuberculous pericarditis in the sub-Saharan African
region, based on clinical and echocardiographic evaluation of
survivors of tuberculous pericarditis [6]. The present study
provides a more accurate estimate of the prevalence of
effusive-constrictive disease in patients with tuberculous
pericardial effusion based on an appropriate sample size [8],
an acceptable case definition of tuberculous pericarditis [10],
and a proven diagnosis of effusive-constrictive disease using
the combination of pericardiocentesis and cardiac
catheterization [1].
The finding that there was a relationship between the height
of the pre-pericardiocentesis right atrial pressures and the
diagnosis ECP was consistent with a similar observation by
Hancock in the original case series on ECP [2]. The
explanation provided then, to which we subscribe, was that the
impact of the compression from the surrounding fluid and
constricting visceral pericardium was additive. Interestingly the
group of patients with ECP in that study as in ours, was
approximately a decade younger than those with effusive non-
constrictive pericarditis. It is possible that age related changes
Tuberculous Effusive-Constrictive Pericarditis
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in the activity of cell mediated responses to infections like
tuberculosis may offer an explanation for this finding [18]. We
were not able to demonstrate an association between ECP and
participant HIV status, or the degree of immunosuppression as
measured by CD4 count. This is important because of
suggestions that HIV might protect against the development
constrictive pericarditis [19].
There have been no studies hitherto of the pathogenesis of
ECP. We have studied the levels of cytokines that play a role in
inflammation and fibrosis to shed light on the immunological
basis of tuberculous ECP. We have found that tuberculous
ECP differs from effusive non-constrictive disease, having a
distinctive cytokine profile characterized by elevated serum
IL-10 and TGF-β and high pericardial fluid IL-10 and IFN-γ.
IL-10 plays a role in the regulation of the immune response to
M. tuberculosis [18], while IFN-γ is a major inflammatory
cytokine responsible for the control and resistance to
mycobacterial infection (Figure 1) [20,21]. Furthermore, IL-10
and TGF-β have important roles in fibrosis following chronic
inflammation [22-25]. While the combination of elevated IL-10
and IFN-γ within the pericardium may reflect a chronic
unresolving inflammatory response to tuberculosis, the
Table 3. Univariable and multivariable logistic regression
analysis for factors associated with effusive constrictive
pericarditis.
Factor Univariable analysis Multivariable analysis
 OR(95%CI)  OR(95%CI)  
Right atrial pressure     
>15 mmHg 59.4(13-271.3) <0.0001 48(8.7-265.2) <0.0001
≤15 mmHg 1  1  
IL-10     
>200 pg/ml 8.53(1.17) <0.0001 9.91(1.1-92.8) 0.04
≤200 pg/ml 1  1  
doi: 10.1371/journal.pone.0077532.t003
Figure 1.  Visual representation of significant cytokine differences when comparing effusive with effusive-constrictive
tuberculous pericarditis in the blood and pericardial fluid compartments (see Table 2 for results of all cytokines).  Each
colored disc represents the median value for the particular cytokine; the areas are proportional to the concentration of the cytokine.
IL-10, interleukin 10; TGF- β, transforming growth factor beta; IFN- γ, interferon gamma.
doi: 10.1371/journal.pone.0077532.g001
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elevated serum levels of IL-10 and TGF-β may be a signal of
early activation of pathways involved in long-term fibrosis
offering a potential explanation for the constrictive physiology
that was observed.
This pattern of cytokine expression may not only establish
effusive-constrictive syndrome as biologically distinct in
addition to the hemodynamic profile, but may have
pathophysiological significance for pericardial remodeling
following injury. The distensible visceral pericardium makes a
vital contribution to cardiac compliance during diastole [26].
Disruption of the architecture of the visceral monolayer of
mesothelial cells by inflammatory injury may impair epicardial
elasticity and compliance, resulting in constriction and diastolic
dysfunction. It has been suggested that in response to
tuberculous antigens, TNF-α may lead to greater tissue injury
in the presence of a mixture of regulatory and inflammatory
cytokines than it does in the presence of either regulatory or
inflammatory cytokines alone [27].
This study has a number of limitations. First, we enrolled
patients with a moderate to a large pericardial effusion that was
amenable to safe pericardiocentesis. This strategy may have
introduced a degree of selection bias, and therefore the
findings of this study apply to patients with moderate to large
pericardial effusions with a probable and a definite diagnosis of
tuberculous pericarditis. Second, a proven diagnosis of
tuberculosis was made in 60% of cases. It is possible therefore
that the 40% of participants with a presumed diagnosis may
have had other inflammatory causes of pericarditis such as
viral infection and autoimmune disease. The proportion of
proven cases of tuberculosis is however typical of experience
in tuberculosis endemic regions of the world [28]. Finally, while
the sample size of 36 cases of ECP may appear to be small,
this study is the largest series of proven cases of ECP to date.
Nevertheless, a larger sample size will be required to provide
reliable information on the outcome of ECP compared to
effusive non-constrictive tuberculous pericarditis[8].
In conclusion, this report provides new information on the
prevalence, hemodynamics, clinical and cytokine profile of
cases of proven and presumptive tuberculous ECP. We show
that effusive-constrictive disease is a common form of
tuberculous pericardial effusion that affects younger patients
with an extremely high pre-pericardiocentesis right atrial
pressure and markedly elevated pericardial and serum IL-10
levels. The cytokine profile is consistent with chronic
unresolving inflammation and fibrosis. These observations lay
the basis for studies of outcome and management of effusive-
constrictive tuberculous pericarditis, a clinical entity that has
hitherto not been addressed in guidelines for the management
of pericardial disease [29].
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